20-valent pneumococcal conjugate vaccine - Biologic Drug Details

Summary for 20-valent pneumococcal conjugate vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for 20-valent pneumococcal conjugate vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Pneumococcal Vaccine
Chemical Structure	Pneumococcal Vaccines Vaccines, Conjugate Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for 20-valent pneumococcal conjugate vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for 20-valent pneumococcal conjugate vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	PREVNAR 20	20-valent pneumococcal conjugate vaccine	Injection	125731	7,935,787	2027-04-19	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	PREVNAR 20	20-valent pneumococcal conjugate vaccine	Injection	125731	9,517,274	2033-08-12	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	PREVNAR 20	20-valent pneumococcal conjugate vaccine	Injection	125731	9,950,054	2036-11-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for 20-valent pneumococcal conjugate vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for 20-valent pneumococcal conjugate vaccine

Country	Patent Number	Estimated Expiration
Finland	C20220032
Japan	6192115
South Korea	20150041139
Spain	2557504
Finland	2676679

Supplementary Protection Certificates for 20-valent pneumococcal conjugate vaccine

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2290026-0	Sweden		PRODUCT NAME: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPES 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F AND 33F, EACH CONJUGATED TO CRM197 CARRIER PROTEIN.; REG. NO/DATE: EU/1/21/1591 20211214
122022000054	Germany		PRODUCT NAME: APEXXNAR - PNEUMOKOKKEN-POLYSACCHARID-SEROTYP 33F, KONJUGIERT AN DAS CRM197-TRAEGERPROTEIN DURCH EINEN (2-((2-OXOETHYL)THIO)ETHYL)CARBAMAT (ETEC)-SPACER; REGISTRATION NO/DATE: EU/1/21/1612 20220214
CA 2022 00034	Denmark		PRODUCT NAME: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F CONJUGATED TO CRM197 CARRIER PROTEIN THROUGH A (2-((2-OXOETHYL)THIO)ETHYL)CARBAMATE (ETEC) SPACER; REG. NO/DATE: EU/1/21/1612 20220215
22C1037	France		PRODUCT NAME: POLYOSIDE PNEUMOCOCCIQUE SEROTYPE 33F CONJUGUE A LA PROTEINE VECTRICE CRM197 PAR L'INTERMEDIAIRE D'UN ESPACEUR (2-((2-OXOETHYL)THIO)ETHYL)CARBAMATE (ETEC).; REGISTRATION NO/DATE: EU/1/21/1612 20220215
PA2022509,C2676679	Lithuania		PRODUCT NAME: PNEUMOKOKINE POLISACHARIDINE KONJUGUOTA VAKCINA (15 VALENTE, ADSORBUOTA) ; REGISTRATION NO/DATE: EU/1/21/1591 20211213

20-valent pneumococcal conjugate vaccine Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for the 20-Valent Pneumococcal Conjugate Vaccine?

The 20-valent pneumococcal conjugate vaccine (PCV20) is an extension of existing pneumococcal vaccines, offering protection against 20 serotypes of Streptococcus pneumoniae. Its market growth is driven by several factors, including rising pneumococcal disease prevalence, vaccine innovation, and evolving immunization guidelines.

Epidemiology and Disease Burden

• Pneumococcal diseases cause approximately 1.6 million deaths annually, mostly in children under five and older adults (WHO).
• Serotype coverage gaps in older vaccines (PCV13) leave survivors vulnerable to disease from additional serotypes covered by PCV20.
• Global pneumococcal vaccine market size was valued at $8.2 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 6.3% through 2030 [1].

Regulatory Milestones and Approvals

• PCV20 received FDA approval in June 2021 for use in adults aged 18 years and older.
• European Medicines Agency (EMA) approved the vaccine in March 2022.
• Ongoing Phase 3 trials for pediatric indications aim to expand approval scopes, influencing future market adoption.

Competitive Landscape

• PCV13 (Prevnar 13): Dominant in children, with significant market share.
• PCV15 (Vaxneuvance): Approved in the US, covers 15 serotypes, close competitor to PCV20.
• Conjugate vaccines typically exhibit high pricing, driven by efficacy and immunogenicity, supporting premium market positioning for PCV20.

Adoption Drivers

• Expanded serotype coverage appeals to health authorities in regions with high disease burden from non-PCV13 serotypes.
• Increasing adult vaccination rates in aging populations, notably in the US and Europe.
• Recommendations from CDC, WHO, and national immunization programs influence uptake.

Constraints and Challenges

• High vaccine costs may limit accessibility in low-income countries.
• Cost-effectiveness analyses influence public sector adoption; benefits must justify higher prices due to added serotypes.
• Competitor vaccines with established markets and clinical data may resist rapid market share shifts.

Global Reach and Market Penetration

• The US accounts for nearly 50% of pneumococcal vaccine sales; PCV20's impact hinges on adult immunization strategies.
• Emerging markets in Asia and Latin America represent growth opportunities, constrained by pricing and healthcare infrastructure.

---

What Is the Financial Trajectory for PCV20?

The financial outlook for PCV20 reflects its positioning as a premium, broad-spectrum pneumococcal vaccine. The trajectory involves initial launch revenues, expansion through approval in various populations, and competitive pressures.

Revenue Projections

• From 2022 to 2027, market analysts project US sales to reach $1.4 billion annually for adult indications, driven by vaccination campaigns and reimbursement coverage.
• European sales are expected to contribute approximately 25-30% of total revenue within the same period, given regulatory approvals and immunization policy adoption.
• The pediatric market remains under evaluation; successful approval could add an estimated $400 million in annual revenues by 2028.

Pricing Assumptions

• US list price: approximately $150-$180 per dose, based on PCV13 and PCV15 benchmarks.
• European prices range from €70 to €100, with variation due to national procurement agreements.
• Bulk purchasing and government tenders tend to lower effective prices.

Cost Factors

• R&D expenditures for PCV20 are estimated at $1.2 billion, including clinical trials, regulatory submissions, and manufacturing scale-up.
• Manufacturing costs per dose are estimated at $25-$35, influenced by conjugate vaccine complexity and antigen production.
• Marketing and distribution expenses constitute approximately 15% of annual revenues.

Growth Drivers

• Expanded adult immunization programs, especially following increased awareness of pneumococcal disease in seniors.
• Introduction into pediatric vaccines, pending approval.
• Potential use in immunocompromised populations, including HIV-positive or transplant patients.

Challenges Limiting Revenue Growth

• Competition from established vaccines could hinder rapid market share gains.
• Price sensitivity in emerging markets slows penetration.
• Reimbursement policies and vaccine hesitancy may constrain rollout speed.

---

How Could Market Trends Evolve?

The future market for PCV20 depends on several evolving factors:

• Broader acceptance of adult pneumococcal vaccination, particularly post-COVID-19, emphasizing vaccine-preventable disease control.
• Expansion into pediatric indications, diversifying revenue streams.
• Policy changes favoring higher-valent vaccines over lower-valent counterparts.
• Competitive developments, including next-generation protein-based pneumococcal vaccines.

Market penetration may accelerate with clearer demonstration of cost-effectiveness and improved public health outcomes. Immediate revenue growth prospects primarily stem from the adult immunization segment, with pediatric and global market expansion contingent on regulatory and reimbursement developments.

---

Key Takeaways

• The global pneumococcal vaccine market is growing, driven by disease burden and vaccine innovation.
• PCV20's regulatory approval in 2021 and 2022 positions it as a key player, with revenue potential in adult populations and emerging markets.
• Pricing strategies, reimbursement policies, and competitors influence financial performance.
• Expansion into pediatric markets and global regions presents significant growth opportunities.
• Market dynamics require continuous assessment of epidemiological trends, clinical data, and policy changes.

---

FAQs

1. What serotypes does PCV20 cover that PCV13 does not?
PCV20 covers seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F) not included in PCV13, broadening disease protection.

2. When did PCV20 receive approval for adult use?
The FDA approved PCV20 for adults aged 18 and older in June 2021.

3. What is the expected global market size for PCV20 by 2030?
While specific figures are uncertain, the pneumococcal vaccine market is projected to reach approximately $13 billion globally by 2030, with PCV20 capturing a significant share in adult and pediatric segments.

4. How do pricing strategies differ across regions?
In the US, list prices are about $150-$180 per dose, supported by reimbursement policies. European prices are lower, around €70-€100, reflecting national tender negotiations. Emerging markets face greater price sensitivity and lower price points.

5. What are the major barriers to PCV20 market growth?
Barriers include high vaccine costs, competition from existing vaccines, regulatory hurdles, and vaccine hesitancy, especially in low-income countries.

---

References

1. MarketWatch. "Global Pneumococcal vaccine Market Size, Share & Trends Analysis Report." 2022.